Search

Your search keyword '"Millward MJ"' showing total 124 results

Search Constraints

Start Over You searched for: Author "Millward MJ" Remove constraint Author: "Millward MJ"
124 results on '"Millward MJ"'

Search Results

1. Editorial

2. The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study

12. Time-course RNAseq data of murine AB1 mesothelioma and Renca renal cancer following immune checkpoint therapy.

13. Immune checkpoint therapy responders display early clonal expansion of tumor infiltrating lymphocytes.

14. Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice.

15. Retinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint Therapy.

16. Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors.

17. A phase 1b clinical trial optimizing regulatory T cell depletion in combination with platinum-based chemotherapy in thoracic cancers.

18. Hydantoin-bridged medium ring scaffolds by migratory insertion of urea-tethered nitrile anions into aromatic C-N bonds.

19. Association of Known Melanoma Risk Factors with Primary Melanoma of the Scalp and Neck.

20. An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer.

21. Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors.

22. Bilateral murine tumor models for characterizing the response to immune checkpoint blockade.

23. Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy.

24. A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer.

25. Free-Wilson Analysis of Comprehensive Data on Phosphoinositide-3-kinase (PI3K) Inhibitors Reveals Importance of N -Methylation for PI3Kδ Activity.

26. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment.

27. Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC.

28. Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity.

29. Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.

30. PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors.

31. A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma.

32. Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT.

33. The aggregation of early-onset melanoma in young Western Australian families.

34. Mycobacterium mimicking metastatic melanoma.

35. A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.

36. Using expert panels to determine the level of cancer knowledge required of junior doctors in australia. Part 2: sources of variability.

37. Using expert panels to determine the level of cancer knowledge required of junior doctors in Australia. Part 1: methodology and results.

38. Role of endobronchial ultrasound in diagnosis and molecular assessment of metastatic melanoma.

39. A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma.

40. The Western Australian Melanoma Health Study: study design and participant characteristics.

41. Applying global frameworks to assessment in medical education: an example of a nationally produced curriculum for cancer education.

42. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters.

43. Long-term survival following chemoradiation for inoperable non-small cell lung cancer.

44. Overexpression and altered glycosylation of MUC1 in malignant mesothelioma.

45. A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.

46. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.

47. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.

48. The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study.

49. Detection of metastatic disease in patients with uveal melanoma using positron emission tomography.

50. Promoter hypermethylation of the O(6)-methylguanine DNA methyltransferase gene and microsatellite instability in metastatic melanoma.

Catalog

Books, media, physical & digital resources